Pristine New Leader — Committed to Becoming a Trusted Global Clinical Research Solutions Provider

Seizing industry development opportunities to provide higher-quality services to clients, Becoming an outstanding partner for innovative Chinese pharmaceutical companies.

Jiang Long believes the Chinese pharmaceutical industry is undergoing a historic transformation. Driven by policy support and expanding market demand, innovation has become an inevitable trend. Whether as an investor or the founder of a CRO company, he personally finds great satisfaction in helping partners successfully bring innovative drugs to market. His decision to assume leadership at Pristine stems from the company's 20-year rich history, having successfully undertaken over 1,800 clinical studies, which has endowed it with extensive experience in drug clinical trials. The company boasts leading management and quality assurance systems, along with a robust talent pipeline, ensuring strong competitiveness in both domestic and international markets. He is confident in leading the Pristine team to seize industry opportunities, provide superior services to clients, and become an exceptional partner for innovative Chinese pharma companies.

The full trust and strong support of all shareholders provide ample resources and funding to build a long-term, stable core team.

As a major shareholder serving concurrently as Chairman and General Manager, Jiang Long enjoys the full trust and strong backing of all shareholders. This provides sufficient resources and financial security to build a stable core team for the long term, laying a solid foundation for Pristine's future steady development.

Ms. Lai Manying, Founding Partner of Inno Capital, stated:
"We are delighted and warmly welcome Dr. Jiang Long to Pristine Pharma! He possesses a global vision and perspective, comprehensive knowledge, and rich hands-on experience in clinical medicine, particularly excelling in international project planning, clinical research, and medical registration. Dr. Jiang Long's joining will significantly enhance the overall strength of the company's operational team, strengthen clinical project strategic planning, and accelerate the company's globalization." As one of Pristine's investors, Inno Capital manages assets exceeding RMB 50 billion and has cumulatively invested in over 300 leading enterprises in sectors like biopharma and new energy. Over 90% of its entrusted funds come from large institutions including financial institutions, state-owned enterprises, and listed companies. It is one of the PE institutions most frequently included on financial institutions' asset manager whitelists.

Mr. Liu Chunguang, Managing Partner of Tailong Investment, expressed warm welcome and congratulations to Dr. Jiang Long for helming Pristine.

He stated: "Whether as an old friend or a new partner, Tailong Investment will continue to support Dr. Jiang Long and Pristine in their further growth and expansion. The Taikun Fund managed by Tailong Investment, as the largest single biopharma industry fund in China, focuses on professional equity investment management in biopharma, medical devices, and the healthcare sector, with an AUM of RMB 20 billion. Tailong Investment will also continue to facilitate deep cooperation and empowerment between its portfolio companies and Pristine."

Providing more partnership models that meet client needs, Collaborating with investment partners to create an upgraded CRO service paradigm.

Jiang Long stated that facing numerous challenges in the clinical trial field—including rising R&D costs, evolving regulations, and intensifying market competition—CRO companies must possess keen market insight, continuously innovative technologies, and efficient management systems. To this end, the company will further refine its organizational structure, optimize internal management processes, and enhance team cohesion. Simultaneously, the company will prioritize talent cultivation and recruitment plans, strengthen employee training and development programs, to build a high-level professional team capable of effectively addressing the pain points of innovative pharma companies in clinical research. It will also offer more partnership models tailored to client needs, working hand-in-hand with investment partners to create an upgraded CRO service paradigm.

Jiang Long aims to propel Pristine into accelerated expansion across key regions in China and into new business ventures, speeding up the realization of the company's vision to "become a trusted global clinical research solutions provider." Concurrently, during its rapid development, Pristine is committed to providing employees with an enhanced career development platform, achieving the mutual elevation of corporate and social value.